SERPINE1 and neoplasm: Out of the newer techniques such as tumor infiltrating lymphocytes, Ki-67, circulating tumor cells, genetic profiles, and PIK3CA analysis, only the uPA/PAI1 analysis as well as the 21-Gene-Recurrence Score have been validated in prospective clinical trials, however, only for specific clinical breast cancer subtypes in primary disease [22–25].